Cell reports · 2022
BCG vaccination provides protection against IAV but not SARS-CoV-2.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaufmann Eva, Khan Nargis, Tran Kim A, Ulndreaj Antigona, Pernet Erwan, Fontes Ghislaine, Lupien Andréanne, Desmeules Patrice, McIntosh Fiona, Abow Amina, Moorlag Simone J C F M, Debisarun Priya, Mossman Karen, Banerjee Arinjay, Karo-Atar Danielle, Sadeghi Mina, Mubareka Samira, Vinh Donald C, King Irah L, Robbins Clinton S, Behr Marcel A, Netea Mihai G, Joubert Philippe, Divangahi Maziar
Аннотация
Since the vast majority of species solely rely on innate immunity for host defense, it stands to reason that a critical evolutionary trait like immunological memory evolved in this primitive branch of our immune system. There is ample evidence that vaccines such as bacillus Calmette-Guérin (BCG) induce protective innate immune memory responses (trained immunity) against heterologous pathogens. Here we show that while BCG vaccination significantly reduces morbidity and mortality against influenza A virus (IAV), it fails to provide protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In contrast to IAV, SARS-CoV-2 infection leads to unique pulmonary vasculature damage facilitating viral dissemination to other organs, including the bone marrow (BM), a central site for BCG-mediated trained immunity. Finally, monocytes from BCG-vaccinated individuals mount an efficient cytokine response to IAV infection, while this response is minimal following SARS-CoV-2. Collectively, our data suggest that the protective capacity of BCG vaccination is contingent on viral pathogenesis and tissue tropism.